Neumora Therapeutics, Inc.
NMRA
$1.20
-$0.05-4.00%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -15.73% | -24.06% | -18.81% | -23.95% | 0.80% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -21.93% | -25.48% | -7.06% | -31.24% | -15.33% |
| Operating Income | 21.93% | 25.48% | 7.06% | 31.24% | 15.33% |
| Income Before Tax | 18.26% | 21.30% | -1.07% | 21.71% | 10.02% |
| Income Tax Expenses | -- | -71.43% | -- | -- | -80.00% |
| Earnings from Continuing Operations | 18.30% | 21.38% | -1.07% | 21.77% | 10.17% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 18.30% | 21.38% | -1.07% | 21.77% | 10.17% |
| EBIT | 21.93% | 25.48% | 7.06% | 31.24% | 15.33% |
| EBITDA | 21.91% | 25.32% | 6.84% | 31.13% | 15.14% |
| EPS Basic | 28.64% | 29.42% | 3.45% | 22.86% | 11.67% |
| Normalized Basic EPS | 28.62% | 29.38% | 3.46% | 29.59% | 11.55% |
| EPS Diluted | 28.64% | 29.42% | 3.45% | 22.86% | 11.67% |
| Normalized Diluted EPS | 28.62% | 29.38% | 3.46% | 29.59% | 11.55% |
| Average Basic Shares Outstanding | 14.52% | 11.41% | 4.68% | 1.42% | 1.70% |
| Average Diluted Shares Outstanding | 14.52% | 11.41% | 4.68% | 1.42% | 1.70% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |